We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA issued a warning letter to Enovachem for serious deviations from current good manufacturing practices for its APIs, in a follow-up to a Sept. 25-27, 2018 inspection of the firm’s Torrence, California manufacturing facility.